BioVie is a clinical-stage company developing drug therapies to overcome unmet medical needs in chronic debilitating conditions. In liver disease, Co.'s orphan drug candidate, BIV201 (continuous infusion terlipressin), is being developed as a future treatment option for patients suffering from ascites and other life-threatening complications of liver cirrhosis caused by nonalcoholic steatohepatitis, hepatitis, and alcoholism. In neurodegenerative disease, Co.'s product candidate, NE3107, is an orally administered small molecule that is thought to inhibit inflammation-driven insulin resistance and primary pathological inflammatory cascades with a mechanism of action. We show 15 historical shares outstanding datapoints in our coverage of BIVI's shares outstanding history.
Understanding the changing numbers of BIVI shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like BIVI versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching BIVI by allowing them to research BIVI shares outstanding history
as well as any other stock in our coverage universe. |
Free BIVI Email Alerts:
Video: Shares Outstanding Importance
